Critical care management of the liver transplant recipient

Critical Care Nursing Quarterly

Volumn 31, Issue 3, 2008, Pages 232-243

  Rudow, Dianne Lapointe ^a   Goldstein, Michael J ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Infections; Liver transplant; Postoperative; Rejection

Indexed keywords

ACETYLCYSTEINE; ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTIMETABOLITE; ANTIVIRUS AGENT; CALCINEURIN INHIBITOR; CIMETIDINE; CLARITHROMYCIN; CYCLOSPORIN; DEXAMETHASONE; DILTIAZEM; DIURETIC AGENT; DOPAMINE; ERYTHROMYCIN; HEPATITIS B ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INSULIN; ISONIAZID; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHENOBARBITAL; PHENYTOIN; PREDNISONE; PROSTAGLANDIN E1; PROTON PUMP INHIBITOR; RIFAMPICIN; STEROID; TACROLIMUS; UNINDEXED DRUG;

ACUTE GRAFT REJECTION; BILE DUCT OBSTRUCTION; BILIARY TRACT DISEASE; CENTRAL PONTINE MYELINOLYSIS; CHRONIC GRAFT REJECTION; CONTINUOUS INFUSION; CONVALESCENCE; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG METABOLISM; ELECTROLYTE DISTURBANCE; FOLLOW UP; FUNCTIONAL ASSESSMENT; GRAFT FAILURE; HEALTH CARE ACCESS; HEPATITIS B; HOSPITAL DISCHARGE; HUMAN; HYPERGLYCEMIA; INTENSIVE CARE; INTENSIVE CARE NURSING; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FAILURE; LIVER FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LONG TERM CARE; NEUROLOGICAL COMPLICATION; ORGAN DONOR; PATIENT SAFETY; PORTAL VEIN THROMBOSIS; POSTOPERATIVE CARE; POSTOPERATIVE INFECTION; POSTOPERATIVE THROMBOSIS; RECIPIENT; REVIEW; STOMACH ULCER; SURGICAL TECHNIQUE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; UNITED STATES; AFTERCARE; CROSS INFECTION; DRUG INTERACTION; GRAFT REJECTION; HOSPITAL ADMISSION; LIVER RESECTION; LIVING DONOR; METABOLIC DISORDER; METHODOLOGY; NURSE ATTITUDE; NURSING; NURSING ASSESSMENT; ORGANIZATION AND MANAGEMENT; PATIENT SELECTION; PERIOPERATIVE PERIOD; RESOURCE ALLOCATION; STATISTICS; THROMBOSIS; TRANSPLANTATION;

AFTERCARE; BILIARY TRACT DISEASES; CRITICAL CARE; CROSS INFECTION; DRUG INTERACTIONS; GRAFT REJECTION; HEPATECTOMY; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; LIVING DONORS; NURSE'S ROLE; NURSING ASSESSMENT; PATIENT DISCHARGE; PATIENT SELECTION; PERIOPERATIVE CARE; RESOURCE ALLOCATION; THROMBOSIS; TISSUE AND ORGAN PROCUREMENT; UNITED STATES; WAITING LISTS; WATER-ELECTROLYTE IMBALANCE;

EID: 49249127468     PISSN: 08879303     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CNQ.0000325048.01776.f2     Document Type: Review

References (25)

1. United Network for Organ Sharing. http://www. unos.org. Accessed March 12, 2008.
2. Scientific Registry of Transplant Recipients. www. ustransplant.org/csr/ current/fastfacts.aspx. Accessed March 26, 2008.
3. Rourke OM. Liver transplantation. In: La Pointe Rudow D, Ohler L, Shafer T, eds. Clinicians Guide to Donation and Transplantation. Lenexa, KS: Applied Measurement Professionals Inc; 2006:457-480.
4. Murray K, Carithers R Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology. 2005;41(6):1-26.
5. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
6. Polson J, Lee WM. AASLD practice guidelines: management of the patients with acute liver failure. Hepatology. 2005;41(5):1179-1197.
7. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91-96.
8. Alkofer B, Samstein B, Guarrera JV, et al. Extended-donor criteria liver allografts. Semin Liver Dis. 2006;26(3):221-233.
9. LaPointe Rudow D, Brown RS Jr. Evaluation of living liver donors. Prog Transpl. 2003;13(2):110-116.
10. Franco-Gou R, Mosbah I, Serafin A, Abdennebi H, Roselio-Catafau J, Peralta C. New preservation strategies for preventing liver grafts against cold ischemia reperfusion injury. J Gastroenterol Hepatol. 2007;22:1120-1126.
11. Emond J. Surgical techniques. In: Norman DJ, Suki WN, eds. Primer on Transplantation. Mt Laurel, NJ: American Society of Transplant Physicians; 1998: 311-318.
12. Crippin J. Pathogenesis/pathology of organ dysfunction. In: Norman DJ, Suki WN, eds. Primer on Transplantation. Mt Laurel, NJ: American Society of Transplant Physicians; 1998:321-327.
13. Randall H, Klintmalm G. Postoperative intensive care unit management: adult liver transplant recipients. In: Busuttil R, Klintmalm G, eds. Transplantation of the Liver. 2nd ed. Philadelphia, PA: Elsevier; 2005: 833-849.
14. Weisner R, Martin P, Stribling R. Post-transplant care/medical complications. In: Norman DJ, Suki WN, eds. Primer on Transplantations. Mt Laurel, NJ: American Society of Transplant Physicians; 1998:343-360.
15. Kornberg A, Grube T, Wagner T, et al. Differentiated therapy with prostaglandin E1 (alprostadil) after or-thotopic liver transplantation: the usefulness of pro-calcitonin (PCT) and hepatic artery resistive index (RI) for the evaluation of early graft function and clinical course. Clin Chem Lab Med. 2000;38(11):1177-1180.
16. Sauer IM, Zeilinger K, Pless G, et al. Extracorporeal liver support based on primary human liver cells and albumin dialysis - treatment of a patient with primary graft non-function. J Hepatol. 2003;39(4):649-653.
17. Nissen N, Colquhoun S. Graft failure: etiology, recognition and treatment. In: Busuttil R, Klintmalm G, eds. Transplantation of the Liver. 2nd ed. Philadelphia, PA: Elsevier; 2005:915-926.
18. Emond JC, Renz JF, Ferrel LD, et al. Functional analysis of grafts from living donors. Implications for the treatment of the older recipient. ANN Surg. 1996;224:544-552.
19. Kim JJ, Dasika NL, Yu E, Fontana RJ. Transjugular in-trahepatic portosystemic shunts in liver transplant recipients. Liver Int. 2008;28(2):240-248.
20. Kim M, Olthoff KM, Merion RM, et al. Outcomes of 385 adult-to-adult living donor liver transplant recipients; a report form the A2ALL consortium. Ann Surg. 2005;242(3):314-325.
21. Weisner RH, Demitris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology. 1998;28:638-645.
22. Coffin CS, Terrault NA. Management of hepatitis B in liver transplant recipients. J Viral Hepat. 2007;14(suppl 1):37-44.
23. Roche B, Samuel D. Risk factors for hepatitis C re-currence after liver transplantation. J Viral Hepat. 2007;14(suppl 1):89-96.
24. Van den Berghe G, Wouters PJ, Bouillon R, et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med. 2003;31(2):359-366.
25. Gabardi S, Baroletti SA, McDevitt LM, Saxer SB, Vaughan FM, Rogers CC. Pharmaceutical care. In: La Pointe Rudow D, Ohler L, Shafer T, eds. Clinicians Guide to Donation and Transplantation. Lenexa, KS: Applied Measurement Professionals Inc; 2006: 613-650.